Comparing Alexza Pharmaceuticals (ALXA) & Endo International PLC (ENDP)
Alexza Pharmaceuticals (NASDAQ: ALXA) and Endo International PLC (NASDAQ:ENDP) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitabiliy, dividends and earnings.
Insider & Institutional Ownership
93.2% of Endo International PLC shares are owned by institutional investors. 0.5% of Endo International PLC shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Alexza Pharmaceuticals and Endo International PLC’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Endo International PLC||$4.08 billion||0.68||$411.84 million||($15.20)||-0.81|
Endo International PLC has higher revenue and earnings than Alexza Pharmaceuticals.
This is a breakdown of current ratings and price targets for Alexza Pharmaceuticals and Endo International PLC, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Endo International PLC||0||14||5||0||2.26|
Endo International PLC has a consensus target price of $16.94, indicating a potential upside of 36.84%. Given Endo International PLC’s higher possible upside, analysts clearly believe Endo International PLC is more favorable than Alexza Pharmaceuticals.
This table compares Alexza Pharmaceuticals and Endo International PLC’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Endo International PLC||-82.93%||25.32%||6.90%|
Endo International PLC beats Alexza Pharmaceuticals on 8 of the 8 factors compared between the two stocks.
Alexza Pharmaceuticals Company Profile
Alexza Pharmaceuticals, Inc. is a pharmaceutical company focused on the research, development and commercialization of products for the acute treatment of central nervous system conditions. The Company’s product candidates are based on the Staccato system technology. Its product candidates in development include AZ-002, which contains alprazolam as an active pharmaceutical ingredient (API) is developed for the management of patients with acute repetitive seizures, and AZ-007, which contains zaleplon as API is developed for the treatment of insomnia in patients who have difficulty falling asleep, including those patients with middle of the night awakening having difficulty falling back asleep. Its product also includes ADASUVE, which contains loxapine as API is developed for the treatment of agitation associated with schizophrenia or bipolar disorder. It has initiated a Phase IIa proof-of-concept study for AZ-002 in patients with epilepsy and has completed Phase I testing for AZ-007.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc. is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel. The Company operates in three segments: Endo Pharmaceuticals, Qualitest and AMS. In June 2014, the Company’s subsidiary, Endo Pharmaceuticals sold its pharmaceutical drug discovery platform to AsanaBioSciences, LLC. In June 2014, Asana BioSciences, LLC, an independent member of Amneal Alliance of Companies, acquired early-stage branded pharmaceutical discovery platform of Endo Pharmaceuticals, a subsidiary of Endo International plc. In June 2014, Trendlines Group acquired intellectual property developed within the framework of an R&D agreement with the Company. In July 2014, it acquired Grupo Farmaceutico Somar.
Receive News & Ratings for Alexza Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexza Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.